119 results about "Osteoporosis treatment" patented technology

A composition and method for producing interconnective macroporous, resorbable and injectable calcium phosphate-based cements (MICPCs). The composition of the invention sets to poorly crystalline apatitic calcium phosphate after mixing a powder component and an aqueous solution. The multiphasic calcium phosphate components in the cement resorb at different rates allowing the timely replacement by new bone. The interconnected macroporosity in the cement allows for vascularization, entrapment of growth factors, cell colonization and tissue ingrowth. This MICPC can be used for dental and medical applications relating to bone repair, augmentation, reconstruction, regeneration, and osteoporosis treatment, and also for drug delivery, and as scaffolds for tissue engineering.

An automatic contextual segmentation method which can be used to identify features in QCT images of femora, tibiae and vertebrae. The principal advantages of this automatic approach over traditional techniques such as histomorphometry are, 1) the algorithms can be implemented in a fast, uniform, non-subjective manner across many images allowing unbiased comparisons of therapeutic efficacy, 2) much larger volumes in the region of interest can be analyzed, and 3) QCT can be used longitudinally. Two automatic contextual segmentation algorithms relate to a cortical bone algorithm (CBA) and a whole bone algorithm (WBA). These methods include a preprocessing step, a threshold selection step, a segmentation step satisfying logical constraints, a pixel wise label image updating step, and a feature extraction step; with the WBA including whole bone segmentation, cortical segmentation, spine segmentation, and centrum segmentation. The algorithms are constructed to provide successful segmentations for known classes of bones with known topological constraints.

The invention describes novel nitrosated and / or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and / or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and / or nitrosylated, and, optionally, at least one nitric oxide donor compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and / or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; and (l) treating nephropathy.

The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and / or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and / or nitrogen via a bond or moiety that cannot be hydrolyzed.

A composition and method for producing interconnective macroporous, resorbable and injectable calcium phosphate-based cements (MICPCs). The composition of the invention sets to poorly crystalline apatitic calcium phosphate after mixing a powder component and an aqueous solution. The multiphasic calcium phosphate components in the cement resorb at different rates allowing the timely replacement by new bone. The interconnected macroporosity in the cement allows for vascularization, entrapment of growth factors, cell colonization and tissue ingrowth. This MICPC can be used for dental and medical applications relating to bone repair, augmentation, reconstruction, regeneration, and osteoporosis treatment, and also for drug delivery, and as scaffolds for tissue engineering.

Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.

A compound of the formula [I]wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like.In addition, an intermediate for the compound is provided.

Disclosed are methods of identifying subjects with osteoporosis or osteopenia, subjects at risk for developing osteoporosis, osteopenia, and bone fractures, methods of evaluating the effectiveness of osteoporosis treatments in subjects with osteoporosis or osteopenia, and methods of selecting therapies for treating osteoporosis or osteopenia, using biomarkers.

The invention describes compositions and kits comprising at least one nitric oxide enhancing angiotensin II antagonist compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing angiotensin II antagonist compound, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension (o) treating central nervous system disorders; (p) treating metabolic syndrome; and (q) treating hyperlipidemia. The nitric oxide enhancing angiotensin II antagonist compounds comprise at least one nitric oxide enhancing group linked to the angiotensin II antagonist compound through one or more sites such as carbon, oxygen and / or nitrogen via a bond or moiety that cannot be hydrolyzed.

The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The organic nitric oxide enhancing compounds that form salts with the angiotensin II antagonists are organic nitrates, organic nitrites, nitrosothiols, thionitrites, thionitrates, NONOates, heterocyclic nitric oxide donors and / or nitroxides. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and / or oxatriazole-5-imines.

The invention relates to an osteoblast targeted vector constructed based on a polypeptide. The targeted vector comprises a target head and a support. The target head is the polypeptide. The grafting mass ratio of the target head is 5-10%, and the mole grafting ratio is 2-6%. The targeted vector is prepared by subjecting the polypeptide and a vector to carboxylic acid covalent linking through polyethylene glycol, and is used for filling medicines treating bone fractures, osteoporosis, osteoarthritis, rheumatoid arthritis or tumor bone metastasis. Compared with the prior art, the targeted vector has osteoblast targeting performance, high bone tissue affinity and efficient medicine delivery capability, and is capable of enhancing osteogenesis effects, reducing medicine using amounts, and reducing cell toxicity and side effects. The targeted vector provides an important medicine delivery tool for future osteoporosis treatment.

The invention relates to a low-frequency electromagnetic field osteoporosis treatment couch controlled by a plurality of parameters such as magnetic induction density, magnetic field frequency and magnetic field type. The treatment couch comprises a couch body; a magnetic field coil is arranged on the periphery of the couch body and is connected with a magnetic field commissioning circuit; the low-frequency electromagnetic field osteoporosis treatment couch further comprises a control unit and a signal conversion unit; the control signal output end of the control unit is connected with the control signal input end of the signal conversion unit; the control signal output end of the signal conversion unit is connected with the input end of the magnetic field commissioning circuit; and the output end of the magnetic field commissioning circuit is connected with the magnetic field coil. The low-frequency electromagnetic field osteoporosis treatment couch can choose the best magnetic field treatment parameter to perform individual targeted treatment as per individual situations of patients, is precision and adjustable in magnetic induction density and frequency of the magnetic field, and can perform effective treatment to patients with osteoporosis or carry out preclusive treatment to patients that need to be bedridden for a long time after receiving a fracture surgery.

A compound represented by the following formula (1), a pharmaceutically acceptable salt thereof or an optically active form thereof: wherein each symbol is as defined in the specification. A compound having a calcium-sensing receptor antagonistic action, a pharmaceutical composition comprising the compound, particularly a calcium receptor antagonist and a therapeutic drug for osteoporosis are provided.

The invention discloses an osterarthritis diagnosis marker which refers to MTUSI gene and expression products thereof. According to gene chip and protein immunization tests, expressions of the MTUSI gene and expression products thereof are lowered in blood and bone tissue of osterarthritis patients as compared with those of the normal; thus, products for diagnosis of osterarthritis can be developed and can be applied to testing expression level of the MTUSI gene or expression products thereof. According to experiment in vitro, bone cell proliferation can be improved by over-expression of the MTUSI gene, and accordingly the MTUSI gene and the expression products thereof can be applied to development of medicines for treating osterarthritis.

A compound of the formula [I]wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.

The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one nitric oxide enhancing group, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; Q) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension; (n) treating ophthalmic disorders; (o) treating metabolic syndrome; and (p) treating hyperlipidemia. The cardiovascular compounds are angiotensin II antagonists, aldosterone antagonists, endothelin antagonists, hydralazine compounds, neutral endopeptidase inhibitors and renin inhibitors. The nitric oxide enhancing groups are nitroxides and / or heterocyclic nitric oxide donors.

The invention discloses a molecular marker for diagnosis and treatment of osteoporosis, wherein the marker for diagnosis and treatment of osteoporosis is KPNA3 gene and expression products thereof. The high-throughput sequencing and QPCR method show that the KPNA3 gene and expression products thereof have differences in expression in bone tissues between normal people and patients with osteoporosis, and according to the correlation between the expression differences, the KPNA3 gene and expression products thereof can be used for serving as the molecular marker for diagnosis and treatment of osteoporosis. In addition, in vivo experiments show that over-expression of the KPNA3 gene can promote the proliferation of bone cells, therefore the KPNA3 gene and the expression products thereof can also be used for development of drugs for treating osteoporosis.

The invention discloses a bone injury / osteoporosis treatment bed based on a multi-physical factor synergistic effect. The treatment bed comprises a head cabin, a liftable ultraviolet-proof eye light-shading plate, banding tapes for fixing arms and legs and a waist, an electromagnetic field generating coil arranged above a bed body, an ultraviolet generator, a control platform, a built-in ultraviolet sensor and an electromagnetic induction coil probe, the electromagnetic field generating coil arranged below the bed body, a bed body angle regulator, movable and adjustable fixed pedals, a pressure sensor and a linear motor. The control platform controls the ultraviolet generator, the electromagnetic field generating coils and the linear motor in a closed loop control mode via a feedback control module. With application of the synergistic effect of three physical factors of the treatment bed, bone loss of osteoporosis patients can be substantially inhibited and bone absorption rate can be reduced. Besides, fracture healing of fracture patients can be facilitated and bone injury restoration can be accelerated.

The invention discloses a bone injury / osteoporosis treatment bed based on high-frequency low-intensity vibration. The treatment bed includes a bed body which is provided with a head rest and a pedal at the two ends respectively. The bottom part of the bed body is provided with an angle adjuster. The angle adjuster adjusts the bed body at the side of the head rest to rise for 0-10 degrees. The pedal is subjected to a preloading force applied by the gravity. The pedal contacts a motor. Vibration stimulation is generated through driving of the motor. A control platform controls the linear motor through a feedback control module. The bone injury / osteoporosis treatment bed based on the high-frequency low-intensity vibration adopts vibration-wave stimulation in a horizontal direction and the bed head is adjustable with a raised oblique range of 0-10 degrees. On the one hand, better force bearing of a patient is facilitated and the distance of the head part and the foot part is adjustable according to the height of the patient and on the other hand, the preloading stress of the gravity of the patient body can be borne so that bone absorption rate of the patient of osteoporosis induced by lack of female hormone can be restrained significantly and thus bone loss is restrained.

The invention discloses a molecular marker for early osteoporosis screening. The molecular marker is a ZNF800 gene or ZNF800 gene expression protein and a fragment, analogue and derivative thereof. The invention further discloses application of the ZNF800 gene in preparation of an early osteoporosis screening product. By conducting general investigation on osteoporosis in the crowd by means of the gene, not only can early osteoporosis screening be quickly and effectively achieved, but also a treatment target and an important basis are provided for prediction and diagnosis on occurrence and development of the osteoporosis and even for osteoporosis treatment in the biological level in future.

The invention discloses a novel low-frequency electromagnetic field osteoporosis treatment bed. The novel low-frequency electromagnetic field osteoporosis treatment bed comprises a bed body, a magnetic field coil, a magnetic field debugging circuit, a sliding guide rail, a low-frequency vibration generator, a low-frequency vibration debugging circuit, a controller and fixing bandages, wherein the magnetic field coil is arranged around the bed body and connected with the magnetic field debugging circuit; the sliding guide rail is arranged on the bed body; the low-frequency vibration generator is arranged inside the bed body and connected with the low-frequency vibration debugging circuit; the controller is arranged on the bed body; the fixing bandages are arranged above the bed body. Magnetic field treatment can be carried out by setting the optimal magnetic field parameters according to personal situations of patients, fixed magnetic field parameters are not preset, and personalized and definitive treatment can be carried out according to actual situations of patients, the magnetic induction intensity of a treatment magnetic field and the magnetic field frequency are accurate and adjustable, various magnetic field types and magnetic field waveforms can be provided, and the optimal treatment effect is ensured.

The invention relates to an application of ginsenoside in the preparation of medicine for treating osteoporosis, and the osteoporosis is glucocorticoid-induced osteoporosis. The advantages of the present invention are: the present invention provides a new application of ginsenosides, which broadens the medicinal scope of ginsenosides; At the same time, it can effectively prevent and treat glucocorticoid-induced osteoporosis, and reduce the osteoporosis caused by hormone therapy in patients; Better treatment for patients with steroid-induced osteoporosis.

The invention discloses a traditional Chinese medicine composition for treating osteoporosis. The traditional Chinese medicine composition is prepared from the following raw materials: angelica sinensis, wine-processed rhizoma chuanxiong, prepared rehmannia root, cortex acanthopanacis, cassia twig, salt-processed bark of eucommia, radix dipsaci, rhizoma bletillae, sand-scorch-processed drynaria rhizome, fossil fragments, pseudo-ginseng, radix astragali, dangshen, calcined native copper, pawpaw, herba epimedii, rhizoma dioscoreae hypoglaucae, ground beeltle, salt-processed semen cuscutae and salt-processed fructus psoraleae. The traditional Chinese medicine composition provided by the invention is capable of remarkably increasing the bone mineral density and relieving bone pain. The traditional Chinese medicine composition prepared from combination of the multiple components has a remarkable and definite curative effect on osteoporosis treatment and no obvious acute toxicity reaction, does not cause anorexia during treatment and is safe and reliable in a clinical medication process.

The invention discloses a pharmaceutical composite for osteoporosis treatment, mainly comprising the following indigents of 5-100 parts of radix paeoniae alba, 5-30 parts of radix glycyrrhizae, 5-30 parts of papaya, 3-20 parts of rhizome of Sichuan lovage, 0.5-6 parts of calcium, 31.25-10 parts of vitamin D by weight. The invention aims to overcome the deficiencies of the prior art, provides a medical composite that can effectively treat osteoporosis, improve pain and spasmus and be difficult to give rise to side effect in gastrointestinal tract. In addition, the invention aims to provide a method for preparing the medical composite.

The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the α4β1 integrin on mesenchymal stem cells and for the surface of bone.

The invention provides a preparation method of hollow mesoporous silica double-drug sustained release microspheres for osteoporosis treatment. The preparation method comprises the following steps: preparing phenolic resin microspheres with uniform particle size in advance by using a hydrothermal method, and then coating the surface with shell silica through hydrolysis-polycondensation by using the phenolic resin microspheres as a template to obtain the core-shell structure microspheres with phenolic resin microsphere as the core and silicon dioxide as the shell; then removing the phenolic resin microspheres as the core through calcination to obtain hollow mesoporous silicon dioxide microspheres, activating hydroxyl groups on the surfaces of the hollow mesoporous silicon dioxide microspheres so as to graft an osteoporosis treatment drug, and loading another drug in the inner cavity of the microspheres. The surface-activated hollow mesoporous silica microspheres are used for a drug carrier, and have the advantages of controllable drug release rate, good biocompatibility, high drug loading rate and encapsulation efficiency, long-acting sustained release of drugs and the like; through combined application of the two medicines, bone formation can be promoted while the activity and function of osteoclast are effectively inhibited, drug resistance of the body can be avoided, and the treatment effect is improved.

The present invention discloses applications of mechanical sensitive miR-138-5p as a drug target in skeleton muscle system diseases. The technical scheme comprises that the microtubule microfilament cross-linking factor 1 involving microRNA occurring in osteoporosis is regulated, and the antisense nucleotide antagomir-138-5p of the miR-138-5p is used for treating osteoporosis or other skeleton muscle system diseases, wherein the antagomir-138-5p reverses the osteoblast bone formation inhibition caused by the mechanical unloading condition at the cell and animal levels, the antagomir-138-5p promotes osteoblast differentiation and bone formation through the targeting condition MACF1, the miR-138-5p of MACF1 is regulated to become the therapeutic target of the osteoporosis, and the antisense nucleotide antagomir-138-5p of the miR-138-5puse is used as the osteoporosis treatment drug.

The invention provides a medicine for enhancing osteoblast bone formation in a targeting manner. An effective component of the medicine is a polypeptide; the polypeptide is composed of two amino acids including serine and aspartic acid; the polypeptide contains 2-50 amino acids; the quantity ratio of the serine to the aspartic acid is (0.25-4) to 1; and the mass content of effective components in the medicine is 50%-60%. Compared with the prior art, osteoporosis treatment is taken as a target, and a micro-molecular active polypeptide derived from in-vivo natural protein is used as a bone target treatment medicine; and the target medicine has a bone formation cell targeting property, a good bone formation promoting capability, low cell toxicity and side effect and relatively low medicine dosage, and provides important medicine selection for osteoporosis treatment in the future.